Nektar 治疗内幕者出售股份,公司股票仍然被机构大量持有。 Nektar Therapeutics insider sells shares, company stock remains heavily held by institutions.

内奸乔纳森·扎列夫斯基(Jonathan Zalevsky)出售了10,300股股份,将他的拥有权减少了3.15%。 Nektar Therapeutics insider Jonathan Zalevsky sold 10,300 shares, reducing his ownership by 3.15%. 生物制药公司以免疫疗法为主, 拥有“Moderate Buy”评级和4.08美元价格目标。 The biopharmaceutical company, focused on immunotherapy, has a "Moderate Buy" rating and a $4.08 price target. 尽管最近股票跌至0.93美元,但主要机构投资者持有公司股票的75.88%,其股份最近有所增加。 Despite recent stock declines to $0.93, major institutional investors hold 75.88% of the company's stock, with some increasing their stakes recently.